Investigation of COVID-19 fear, treatment compliance, and metabolic control of patients with type 2 diabetes mellitus during the pandemic

Basit Öğe Kaydı
dc.contributor.authorMenekli, Tugba
dc.contributor.authorYaprak, Bulent
dc.contributor.authorTureyen, Aynur
dc.contributor.authorSenturk, Sibel
dc.date.accessioned2024-08-04T20:59:41Z
dc.date.available2024-08-04T20:59:41Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAims: This study was carried out to investigate fear levels, treatment compliance, and metabolic control of type II Diabetes Mellitus patients during the COVID-19 pandemic.Methods: The study employed a single-center, observational design and was conducted between January and April 2021. The study consisted of 303 patients who attended the internal medicine outpatient clinic of a uni-versity hospital in Turkey. For data collection, the Patient Identification Form, COVID-19 Fear Scale, and the Type II Diabetes Treatment Compliance Scale were used. The study complied with the Helsinki Declaration criteria. IBM SPSS v25.0 statistics package program was used for data analysis.Results: The mean age of the patients was 45.8 +/- 7.5 years, the mean duration of illness was 8.2 +/- 3.6 years. Moreover, 40.6% of patients presented with poor levels of treatment compliance. In addition, the mean FCV-19S score of the patients was 29.1 +/- 3.05. It was noticeable that those with high mean scores of FCV-19S had poor compliance with treatment and metabolic control during the pandemic (p < 0.05). Practice implications: Fear of COVID-19 negatively affects treatment compliance and metabolic control of type II diabetes patients. The patients avoided attending their regular follow-ups at the hospital due to fear of con-tracting COVID-19. In order to reduce the fear of COVID-19 it is paramount to maintain optimum metabolic control and treatment compliance.en_US
dc.identifier.doi10.1016/j.pcd.2022.08.005
dc.identifier.endpage663en_US
dc.identifier.issn1751-9918
dc.identifier.issn1878-0210
dc.identifier.issue5en_US
dc.identifier.pmid36030171en_US
dc.identifier.startpage658en_US
dc.identifier.urihttps://doi.org/10.1016/j.pcd.2022.08.005
dc.identifier.urihttps://hdl.handle.net/11616/103450
dc.identifier.volume16en_US
dc.identifier.wosWOS:000875619200008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofPrimary Care Diabetesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFear of COVID-19en_US
dc.subjectType 2 Diabetesen_US
dc.subjectTreatment complianceen_US
dc.subjectMetabolic controlen_US
dc.titleInvestigation of COVID-19 fear, treatment compliance, and metabolic control of patients with type 2 diabetes mellitus during the pandemicen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu